Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)

v3.20.1
Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue $ 7,152 $ 8,629
Collaboration and License Agreements and Supply Agreements    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 7,152 8,629
Collaboration and License Agreements and Supply Agreements | Bristol-Myers Squibb Company ("BMS")    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 2,045 1,575
Collaboration and License Agreements and Supply Agreements | Merck    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 2,777 4,635
Collaboration and License Agreements and Supply Agreements | SutroVax    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 36 281
Collaboration and License Agreements and Supply Agreements | Merck KGaA, Darmstadt, Germany “EMD Serono”)    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue $ 2,294 $ 2,138